{"entity":{"id":"nct03476681","kind":"trial","name":"Study of NEO-201 in Solid Tumors Expansion Cohorts","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Precision Biologics, Inc, active and no longer recruiting.","summary":"Study of NEO-201 in Solid Tumors Expansion Cohorts is a phase 1/2 interventional study registered as NCT03476681 by Precision Biologics, Inc, with 121 participants planned, started 2019-01-18 and due to reach its primary completion in 2026-06-17. Interventions recorded: NEO-201 in combination with pembrolizumab. Conditions listed: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03476681","url":"https://clinicaltrials.gov/study/NCT03476681"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","head-and-neck","cervical"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct03476681-j-exp-clin-cancer-res-2023"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03476681","phase":"1/2","setting":"Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors","sponsor":"Precision Biologics, Inc","started":"2019-01-18","startedType":"actual","enrolled":121,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03476681/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"paper":[{"id":"paper-nct03476681-j-exp-clin-cancer-res-2023","kind":"paper","name":"First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors","route":"/key-papers/paper-nct03476681-j-exp-clin-cancer-res-2023/"}]}}